This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (18)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Hypertension  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Diuretics vs -Blockers for Treatment of Hypertension

Lessons From ALLHAT

Louis Lasagna, MD

JAMA. 2000;283:2013-2014.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The "graying" of the population has increased the number of patients with hypertension, threatening these patients' quality and length of life. The challenge for physicians treating patients with hypertension is to normalize blood pressure effectively, with as few therapeutic misadventures and medication-related symptoms as possible, at the least possible cost.

Early in the development of antihypertensive agents, it was generally assumed that comparative trials of specific antihypertensive agents were unnecessary because treatments that lowered blood pressure equally were likely to yield equal clinical benefit. This belief led to the use of blood pressure as a surrogate marker and sufficient basis for approval for labeling drugs for use as antihypertensive agents.¹ However, as new drugs were developed with very different mechanisms of action and adverse event profiles, this theory began to be reevaluated. In fact, it seems likely that certain groups of patients—such as those with diabetes, left . . . [Full Text of this Article]

Author Affiliation: Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Mass.

RELATED ARTICLE

Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
JAMA. 2000;283(15):1967-1975.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Blockade of both {alpha}1A- and {alpha}1B-adrenergic receptor subtype signaling is required to inhibit neointimal formation in the mouse femoral artery
Hosoda et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H514-H519.
ABSTRACT | FULL TEXT  

Knockout of the alpha 1A/C-adrenergic receptor subtype: The alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure
Rokosh and Simpson
Proc. Natl. Acad. Sci. USA 2002;99:9474-9479.
ABSTRACT | FULL TEXT  

Should New Drugs Be Used Without Outcome Data?: Implications of ALLHAT and ELITE II
Kaplan
Arch Intern Med 2001;161:511-512.
FULL TEXT